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Introduction

Structural organization of nuclear receptors
The nuclear receptor (NR) superfamily consists of 48 members that are structurally related, but have functions in all kinds of physiological processes and, in connection with that, diseases. Their key role in these processes makes them a very attractive drug target. NRs have a conserved domain organization starting at the N-terminus with the highly variable N-terminal domain (NTD) . For most NRs this domain contains a ligand-independent activation function (AF1). The NTD is intrinsically disordered (ID), but the interaction with binding partners can induce folding which can enhance transcriptional activity. 1, 2 The NTD is followed by the DNA binding domain (DBD) which uses its two zinc fingers to recognize specific hormone response elements (HREs). The affinity for specific HREs is dependent on the NR subtype and NR homo-or heterodimerization, or in some cases monomeric binding to extended HREs. 3 The DBD is connected to the ligand binding domain (LBD) via a hinge region that typically contains a nuclear localization signal and undergoes posttranslational modifications. 4 The LBD is a highly conserved domain typically built up out of 12 helices which are organized in an antiparallel, globular arrangement. 5 The classical "mouse-trap" model states that when an agonistic ligand binds in the ligand binding pocket (LBP), helix 12 (H12) covers the pocket and creates a surface suitable for coactivator binding. 6 Nowadays, this model is under debate and an alternative "dynamic stabilization" model is evoked. 7 This concept states that the LBD in its apo form is in a partially molten state and can adopt a wide range of conformations. Agonist binding stabilizes the fold of H12 and the surface elements required for coactivator binding in the active conformation. 8 Inverse agonists, on the other hand, can increase corepressor recruitment which represses transcription in constitutively active NRs. 9 Antagonists do not cause cofactor recruitment, but do prevent agonist binding and therefore passively repress transcription. 9 C-terminal to the LBD, certain NRs have an additional F-domain that has a variable length and has functions ranging from interacting with other proteins to stabilizing the ligand bound conformations of the LBD. 10 
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A C C E P T E D ACCEPTED MANUSCRIPT transcriptional activity were, as a result, enhanced. 26 Similar observations were found for the mineralocorticoid receptor (MR) and progesterone receptor (PR) which supports the notion that there is a common mechanism of regulation via the NTD, despite its poorly conserved sequence. 27, 28 Homodimerization or heterodimerization with the retinoid X receptor (RXR) is a common phenomenon for NRs. These processes, similar to the binding of other protein partners, change the structural plasticity, and thereby the behavior of a NR. 29 This, in turn, can allosterically affect the recruitment and binding of ligands. As an example, the retinoic acid receptor β (RARβ) is known to be a monomer in solution, but upon binding of cofactors, it forms a homodimeric assembly. 30 Similar behavior was found for VDR and TR when bound to coactivators. 31, 32 In order to dimerize, the receptor has to undergo a conformational change, which can lead to asymmetry in the dimer complex. For both RARβ and the estrogen receptor α (ERα) it was observed that in the homodimer complex, this asymmetry was altering the binding mode of the ligand, as revealed for example via two different poses of the same ligand in each the two monomers. 33, 34 Furthermore, it has been reported that also in the absence of a ligand, the NR homodimer can be asymmetric. The crystal structure of the apo-PPARγ LBD contains two monomers in the asymmetric unit forming a homodimer, with only one of the monomers present in its active conformation. 35 The above summary acts to illustrate that NR regulation involves several allosteric mechanisms. For a more detailed review on this subject the reader could consider an extensive review by Fernandez. 36 Despite these various endogenous allosteric mechanisms, the number of actual endogenic molecules known to act via allosteric pockets on the NR, is extremely limited. In this review, allosteric processes in NR modulation using small molecules will be discussed. Allosteric NR modulation by synthetic small molecules is a relatively new area of research, in contrast to the classic targeting of the orthosteric LBP. 37 While extremely successful, targeting NRs via the orthosteric LBP also brings along certain limitations and challenges. 38 Selectivity issues can arise due to a high degree of similarity in the LBP between certain NRs, which can lead to side effects. Furthermore, mutations can occur in the LBP upon prolonged drug-treatment, which can lead to drug resistance or even agonist/antagonist switching. [38] [39] [40] Allosteric modulation of NRs with small molecules, via targeting binding sites beyond the orthosteric pocket, could therefore be a valuable alternative way of targeting NRs that could potentially overcome some of the described shortcomings of orthosteric ligands.
In this review, first the general concept of allosteric modulation in drug discovery is discussed, specifically focused on the different types of receptor classes, as a background setting and inspiration M A N U S C R I P T
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Small molecule allosteric modulation in drug discovery
Allosteric small molecule modulators and their potential in drug discovery
The vast majority of receptor classes possess endogenous ligands that bind to a defined site, typically termed the orthosteric binding site. Most drugs on the market are similarly targeting these orthosteric pockets and are in essence thus competing with the endogenous ligands. 37, 38, 41 Allosteric ligands bind to sites on proteins that do not overlap with the orthosteric site and are therefore potentially resistant to orthosteric competition. 42 For multiple receptor classes, such as GPCRs and ligand-gated ion channels, but also for enzymes, a significant number of allosteric modulators have already been identified with considerable success. [43] [44] [45] [46] [47] Especially for GPCRs and proteins kinases, multiple allosteric ligands have been identified with some being approved by the FDA, such as Sensipar and Gleevec, and multiple drugs are undergoing clinical trials. 45, 48, 49 For some of these proteins, allosteric modulation might be the sole option to selectively target them because of the evolutionarily conserved nature of their orthosteric site, such as the ATP binding site of kinases. 50 Within the last two decades, an increasing number of connected publications can be observed, demonstrating the growth in interest and development of allosteric modulators ( Figure 2 ). During this time, multiple excellent review articles have been published for receptor classes that can be targeted by allosteric modulators. 11, 43, 44, 46, 47, 51 NRs have similarly seen an increase in attention regarding the identification of allosteric ligands, but here the number of publications is still lagging strongly behind those for other receptor classes. 
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The rapid increase in the attention for allosteric modulators can be explained by several key advantages such ligands have in comparison with orthosteric ligands. First, allosteric sites show greater structural diversity compared to the more conserved orthosteric sites. This could thus lead to a higher degree of selectivity for closely related proteins. 39, 52, 53 Second, as mentioned earlier, allosteric compounds are typically not in competition with the receptor's endogenous ligand. Therefore, allosteric modulators could eventually be used at lower concentrations resulting in reduced side effects. Furthermore, in the case of drug-resistant mutations in the orthosteric binding site, allosteric ligands can pose a promising alternative entry. In addition, since the binding of the allosteric ligand can potentially modulate the binding affinity and efficacy of the orthosteric ligand, a pathway is provided to fine-tune the physiological response of the both. Finally, the chemical structure properties of allosteric ligands are slightly more beneficial over orthosteric ones, as explored by Westen et al. 42 Most importantly here, allosteric modulators appear to be more rigid and they adhere slightly better to Lipinski's rule of 5 which gives a higher potential for good oral drug uptake. 42 Despite these favorable characteristics, the challenge of discovering allosteric drugs is a highly relevant current limitation, since allosteric sites are often not identified or lack specific assay formats for target ligand screening. 53 At present, the majority of potential drug molecules are identified using high-throughput screening (HTS), for which the binding affinity of the ligand is often a hallmark to define the quality of the hit. The orthosteric site can, however, be expected to be dominant in this aspect, limiting the identification of ligands with allosteric binding modes. In addition, especially allosteric ligands for GPCRs are notorious to have a flat 'SAR', meaning that minor modifications on the modulator scaffold lead to a complete loss of activity, further complicating the discovery and optimization of these ligands. 54 The different modes-of-action of allosteric modulators described in literature, as well as the different assay techniques developed for the identification of such allosteric ligands, can serve as inspiration for allosteric targeting of NRs. A compact summary of these concepts, illustrated with selected highlights, as described for other receptor classes is therefore discussed below.
Mechanisms of action of allosteric receptor modulators
The mechanisms by which allosteric modulators exert their function has been investigated in molecular detail, especially using crystal-and solution-based structural data. Allosteric modulators can induce an altered physiological response in multiple ways, because their binding changes the preference of populating certain protein conformations, alone or in consort with an endogenous ligand for the orthosteric site ( Figure 3 ). The section below is geared mostly to membrane proteins and specifically M A N U S C R I P T
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GPCRs as the studies of these proteins serve as important illustrative examples for the much less investigated small molecule NR allosteric modulation.
The majority of the allosteric ligands present in literature bind to pockets in an area surrounding the canonical binding site. This, in turn, influences the binding affinity and efficacy of the orthosteric ligand ( Figure 3A ). 45, 55 Benzodiazepines are a group of very successful modulators that bind to the Gammaaminobutyric acid A (GABA A ) receptor on the extracellular domain (ECD). 39, 56 Binding induces a significant conformational shift in the protein, leading to a greatly enhanced affinity for the natural ligand GABA. 57 Nevertheless, an allosteric molecule does not have to be in close proximity of the orthosteric site to alter the binding kinetics of the endogenous ligand. Multiple examples are known in literature where allosteric ligands bind to a distant site while still exerting an influence on the endogenous ligand. 45, [58] [59] [60] This arises from the fact that allosterically induced conformational shifts can be at one part of the protein, but can also change the conformation of the entire protein. 60, 61 The dimerization behavior of a protein can also be altered by allosteric ligands ( Figure 3B ). Allosteric modulation of receptor tyrosine kinases (RTKs) primarily involves monoclonal antibodies targeting the ECD. [62] [63] [64] The function of the RTK HER2/neu, which is involved in breast cancer, can be inhibited by antibodies using specifically two approaches. Trastuzumab binds to subdomain IV of the HER2/neu RTK thereby inhibiting its activation. Pertuzumab, on the other hand, interacts with subdomain II, which inhibits the activation by blocking dimerization. 62, 65 Also, for the insulin RTK antibodies were identified that influence dimerization behavior. 66, 67 Very recently, the covalent modulator JZ-5209 was identified to bind to the β-Glucocerebrosidase (GCase). This small molecule covalently binds to a lysine residue which is present at the dimerization interface of the GCase, enhancing dimerization and exposing the active site. 68 Intrinsically disordered (ID) protein domains have also come to the forefront for allosteric regulation with small molecules ( Figure 3C ). The absence of a defined secondary structure in these domains makes them devoid of a classical binding pocket. 69, 70 Nevertheless, small molecules and macromolecules have been shown to be capable of binding to these regions and of subsequently inducing a defined secondary structure. 71, 72 The protein tyrosine phosphatase 1B is a therapeutic target for both diabetes and obesity.
This protein contains an ID domain at its C-terminus which is located close to the catalytic domain. The small molecule MSI-1436 binds to this ID site with high affinity, thereby locking the protein into an inactive conformation and reducing the phosphatase activity. 73 
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Bitopic ligands, also known as dualsteric ligands, are allosteric modulators in which the orthosteric and allosteric pharmacophore are covalently linked, allowing them to bind to both pockets simultaneously ( Figure 3D ). Apart from ensuring a stronger binding of the bitopic ligand to the receptor, the additional allosteric pharmacophore can lead to an improved selectivity and a nuance in receptor activation. [74] [75] [76] The bitopic ligand THRX160209 targets the muscarinic M 2 acetylcholine receptor (mAChR), which is a member of the GPCR protein family. For this receptor, the orthosteric site, located in the narrow cavity formed by the seven transmembrane helices, and the allosteric site, located in the ECD, are in close proximity of each other. By combining both pharmacophores, the binding affinity was enhanced with several orders of magnitude. Interestingly, THRX160209 showed to have a superior specificity for the M 2 subtype over other four very homologous subtypes. 77 A similar mode of action is observed for the bitopic ligand SB269652, which binds to both D2 and D3 dopamine receptors with high affinity. In the D 2 R dimer, SB269652 binds to one monomer which reduces the binding of the orthosteric agonists and inverse agonists in the other monomer. 78 Certain receptor proteins contain allosteric pockets featuring a reactive group that can be addressed with a covalent ligand ( Figure 3E ). From a therapeutic point-of-view, such reactive groups are especially relevant when they represent mutated residues correlated to disease development. An example of a covalent modulator is the previously discussed compound JZ-5209, which enhances the dimerization of GCase. 68 In addition, the GTPase K-Ras can be targeted mutant specifically, exploiting the oncogenic G12C mutation. This mutation diminishes the GTP hydrolysis and is closely located to both the nucleotide and the effector binding pocket. By covalently linking compounds to this cysteine residue, the compounds allosterically control the GTP affinity and the normal function of the enzyme can be restored. Since these compounds make use of a mutated residue, the natural protein is not affected. 79 A final example of allosteric modulation relates to ion channels, responsible for the ion exchange over the cell membrane and of particular relevance in the central nervous system. In general, ion channels are either activated by ligand binding to the extracellular domain, in the case of ligand-gated ion channels, or through a change in membrane potential, in the case of voltage-gated ion channels. 80, 81 
Techniques for the identification of allosteric ligands
The increase in focus on the modulation of proteins by allosteric ligands comes with a concurrent demand for novel screening techniques that both aid in the identification of allosteric pockets and in the discovery of small molecule specifically targeting these pockets. Some of the most promising techniques and examples, including computational approaches, fragment soaking, tethering and phage display, are shortly summarized mentioned here to act as a potential framework to be translated to NRs.
Crystal structures of ligand-bound proteins provide high-resolution information about the binding mode of the ligand. The resulting static picture can be further refined with techniques providing dynamic information. 85 Over the last decades, numerous computational methods have been developed to provide a better understanding of the dynamic behavior of the protein, which is of high relevance for M A N U S C R I P T
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the identification of allosteric sites. [86] [87] [88] [89] [90] The computer-aided drug design allows to help understand how allosteric modulators exert their function. 91 Making use of molecular dynamics, ligands could successfully be identified that allosterically bind to the β2-adrenergic class of GPCRs. Also, a hidden allosteric site in the oncogenic K-Ras4B protein was found using molecular dynamics by sampling a conformation of the protein which was not observed in the crystal structure. 88 Fragment-based drug discovery is achieving a strong impact for discovering allosteric binding sites, for example via X-ray crystallography based fragment soaking approaches. 92 Typically, cocktails of 5-10 fragments are soaked into a crystal of the protein of interest. 92, 93 When one or more fragments bind to the protein the additional electron density directly reveals the location of the fragment's binding pocket and the structure of the fragment. As an example, for the HIV-1 reverse transcriptase enzyme, three new binding sites were found that also proved to be inhibitory in enzymatic assays. 93 Similarly, for tyrosine phosphatase 1B 11 binding sites outside the active site have been elucidated. 94 Tethering is not only a technique applied to discover covalent drug binding or orthosteric drugs, but it could also be considered as a technique to identify ligands for allosteric pockets. Different tethering strategies have been developed, of which for example disulfide tethering is well-known. This technique involves the formation of a reversible disulfide bond via the linking of a thiol-containing fragment to a, potentially genetically introduced, cysteine residue in a protein. 95, 96 At equilibrium, the mixture will consist predominantly of the protein bound to the fragment with the highest binding affinity. By use of the covalent bond formation between the fragment and the protein, the affinity of the fragment for the target protein is amplified, which can be useful for detection at lower concentrations. The direction of the ligands to a specific site makes the approach particularly useful in case of a known allosteric site for which novel allosteric ligands should be identified.
Phage display methods have been used occasionally in the search for allosteric receptor modulators. The technique involves the expression of a random library of peptides on the coat proteins of bacteriophages. 97 By physically linking the peptide and its genetic material, novel ligands with desired properties can be easily identified via this approach. A recent study by Tipps et al. uses a combination of phage display technology and standard electrophysical testing for the discovery of novel allosteric modulators for the glycine receptor, a member of the superfamily of ligand-gated ion channels. 98 The unbiased nature of the phage display technique provides potential for the identification of allosteric modulators for targets of which specific allosteric pockets have not yet been identified.
Nuclear Receptor allosteric modulators
NRs, like other receptors, have been targeted on allosteric sites. At the moment, the most studied allosteric modulators include those that target the AF-2 cofactor binding site, the DBD or DNA response elements, modulate the receptor dimerization, modulate PTMs or target alternative sites in the LBD.
These different classes will be discussed briefly, with the main focus on the alternative pockets in the LBD. In the context of this review, allosteric compounds are considered as compounds that bind at a different site than the orthosteric site and lead to stabilization / induce of other NR conformations, and not only inhibit, for example, DNA or coactivator binding (to the DBD or AF-2 site).
Approaches for allosteric modulation of NRs on and beyond the Ligand Binding Domain
NRs are typically activated by the binding of agonistic ligands, resulting in the recruitment of specific cofactors leading to a certain biological response via enhanced gene transcription. One type of alternative NR modulation is, therefore, via the direct inhibition of cofactor binding at the AF-2 site ( Figure 4A ). 99 Many types of AF-2 site inhibitors have been described, such as constrained peptides, peptide mimetics and small molecule inhibitors, all typically mimicking the helical LXXLL cofactor binding motif. 37, 38, 41 This form of direct inhibition of NR-protein interactions is described by other reviews in this issue and therefore not further elaborated here. Targeting the DBD is, therefore, another potential strategy for NR modulation. 37, 38 The first option is the blocking of specific HREs at the DNA, inhibiting the binding of the NR DBD ( Figure 4D ). The most common examples of this approach are hairpin polyamides that non-covalently bind to the minor groove of DNA and thereby disrupt the interaction with the NRs such as ERα and AR. 38, 100, 101 The second strategy is via ligands that target the zinc fingers of the DBD ( Figure 4E ). Zinc fingers play an important role in stabilizing the DBD, meaning that disrupting these zinc fingers results in a destabilization of the DBD leading to a reduction of DNA binding. 38, 102 Most modulators are oxidizing agents that focus on disrupting the Zn-S interaction; they displace the zinc ion in the zinc finger and cause disulfide bond formation of the cysteines that normally coordinate the zinc ions via electrostatic interactions. 38 The most challenging issue for designing such modulators is to achieve selectivity over other NR members since the DBD and is the most highly conserved domain in this class of proteins. 38 Targeting the DBD and HRE interactions will also be discussed in detail elsewhere in this issue.
NR homo-and heterodimerzation also provide entries for allosteric modulation via small molecules ( Figure 4B ). Through its ability to form heterodimeric assemblies, RXR can modulate and activate multiple NR partners such as PPAR, LXR and Nurr1. In general, RXR dimerization partners can be arranged into two classes, being permissive and non-permissive heterodimer partners. For permissive heterodimers, the sole presence of the RXR ligand is enough to make the heterodimer transcriptionally active. If the partner's ligand is also present, this results in a stronger activation. In contrast, for nonpermissive heterodimers, the partner's ligand is required for activation, since they are not responsive to rexinoids on their own. However, like permissive heterodimers, the presence of an RXR ligand does enhance the biological response. The structural mechanism by which RXR transduces its signal to its dimer partner has been further elucidated recently. 103 As an example of the fine interplay of RXR heterodimer regulation, in a Parkinson's disease mouse model, treatment with the RXR agonist bexarotene enhanced the clearance of β-amyloids, improving the neural function. This is believed to be caused by the activation of the permissive RXR-PPAR and RXR-LXR heterodimers. 104 Furthermore, it has been shown that the type of RXR ligand can have a substantial effect on the dimerization behavior of RXR and therefore on the transactivation to its dimer partner. [105] [106] [107] The RXR ligand LG101506 was shown to selectively activate RXR-PPAR heterodimers over other heterodimers e.g. RXR-RAR, RXR-LXR and RXR-FXR. Selective activation of RXR-PPAR has been shown to be beneficial in the treatment of type M A N U S C R I P T
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influencing the heterodimerization of RXR with the orphan NR Nurr1 were analyzed. Interestingly, ligands that introduced steric bulk towards either H7 or H11 of RXR significantly inhibited the heterodimer formation. It is postulated that this behavior is observed because of the presence of Nurr1 H12 making contact with H7 and H11 of RXR at the dimerization interface. 110 Several ligands are known that allosterically modulate NRs by acting at or via PTMs ( Figure 4C ). For PPARγ, for example, phosphorylation of S273 was found to increase insulin sensitivity by upregulating a specific set of target genes without fully activating the receptor. 111 When compounds with minimal agonistic activity bind the PPARγ LBP, there is inhibition of S273 phosphorylation without causing PPARγ activation associated side-effects. 112 A similar modulatory effect might be achievable for other NRs since ligand-induced PTMs are common. In the case of the farnesoid X receptor (FXR), agonist-activated SUMOylation at K277, which is necessary for the transrepression of pro-inflammatory genes, is inhibited by acetylation at K217 in obese individuals. 113 Targeting this acetylation site is postulated as an approach to improve hepatic inflammation and glucose tolerance. 113 A different approach to target a PTM using small-molecules to alter NR activity was shown for the estrogen receptor alpha (ERα), for which a phosphorylation site in the F-domain was identified which interacts with the hub-protein 14-3-3. 114 This interaction can be stabilized by the small molecule Fusicoccin, which reduces ERα dimerization, resulting in inhibition of downstream gene expression. 114 Such PTMs beyond the LBD might provide an advantage over ligand-induced resistance mutations in the LBD. 115 
Allosteric pockets on and in the NR LBD
The major part of this review is dedicated to compounds that bind to allosteric sites within the LBD, which we have categorized into three sub-groups, depending on their binding location ( Figure 5 ). The first group, targeting expanded orthosteric sites, binds (part of) the orthosteric and subsequently extends from there into additional pockets that are unique for a certain NR. The compounds in the second group, the dual site binders, bind the LBD in a two to one stoichiometry where typically one of the two ligands binds in the LBP and the second ligand binds a surface exposed site elsewhere on the LBD. The third group of compounds addresses pockets fully outside of the orthosteric LBP, which we will term alternative pockets. 
Expanded orthosteric site
The size and plasticity of the orthosteric pocket greatly varies between different NRs, ranging from barely existing to as big as 1600 Å 3 . 116 In the past, there has been structural evidence that ligands, especially fatty acid analogs, can bind to the orthosteric LBP of various NRs with a different binding mode. Therefore, NRs can recognize the same ligand but binding can lead to another biological response. 117, 118 In this section, we explore ligands that take it one step further by binding to the orthosteric LBP and extending out to neighboring pockets connected to the classical LBP. These ligands 
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FXR
The farnesoid X receptor (FXR) contains an extra binding site connected to the orthosteric LBP. FXR is a NR that regulates lipid, glucose and amino acid metabolism. 119 The extra binding site was initially found by a molecular modeling study which docked E/Z-guggulsterone in a new pocket defined by both the loop between H1 and H2, and H3, H5, and H8 ( Figure 6A ). 120 The location of this pocket, defined as the S2 site, was later confirmed via HDX-MS studies, but no crystallographic data is currently available. 121 When bile acids, the endogenous ligands of FXR, bind to the receptor the carboxylic acid moiety of the side chain points towards the back of the LBD close to the loop between H1 and H2, and H3 and H5 ( Figure 6A ). 122, 123 This is of particular interest, since for other NRs that bind cholesterol metabolites this part of the ligand points in the direction of H12. When overlaying the crystal structure of FXR cocrystallized with chenodeoxycholic acid (CDCA), the most potent endogenous ligand, with the docked pose of E/Z-guggulsterone it can be appreciated that the carboxylic acid tail points towards the S2 site. 123 Pellicciari et al. used this information to design a ligand library with the carboxylic acid position of CDCA exchanged with chemically diverse groups. 123 Modification of this part of the ligand scaffold yields compounds that expand out of the classical LBP which leads to effects ranging from antagonism to partial and full agonism. This research was continued by further exploring the bile acid scaffold, leading to the discovery of molecules with a high efficacy and affinity. 124, 125 This approach of gaining selectivity by targeting the unique properties of a single NR exemplifies the utility of targeting allosteric pockets. In addition to the S2 site, it has been shown that the orthosteric LBP of FXR can expand by shifting H2 and H6 outwards, generating additional space in the LBP. Therefore, FXR can accommodate larger sized compounds such as ivermectin that alters the cofactor binding pattern of FXR by allosterically enhancing the flexibility of the cofactor binding site ( Figure 6B ). 126 
LRH-1
The binding of liver receptor homolog-1 (LRH-1) to phospholipids is also an example of NR modulation via addressing an expanded orthosteric site. Tuning the activity of LRH-1 can be beneficial in multiple types of cancer and metabolic diseases. 127 In a study by Musille et al., the crystal structure of LRH-1 with phospholipid dilauroylphophatidylcholine (DLPC) was solved at a resolution of 1.8 Å, revealing the binding site of this phospholipid ( Figure 6C ). 128 It could be clearly observed that DLPC is located near the β-sheet-H6 region and makes contacts with residues of H3, H5, H6 and H7. In this binding mode the compound occupies not only the LBP, but also extends out of the canonical pocket. In a second study, crystallography and molecular modeling were combined to identify an allosteric network connecting the novel extended binding pocket with the AF-2 site via the orthosteric LBP, elucidating an allosteric M A N U S C R I P T
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mechanism for the activation of LRH-1 by phospholipids such as DLPC. 129 A highly similar binding mode is observed in the other member of the steroidogenic factor-like subfamily, the steroidogenic factor-1 (SF-1). 130 Blind and coworkers confirmed via biochemical and structural analysis that phospholipid PIP 3 stabilizes the previously determined critical H2-3 and H11-12 loops thereby enhancing coactivator recruitment. 130, 131 Finally, a related example is the glucocorticoid deacylcortivazol (DAC) which binds to an extension of the LBP located at the top half of the LBD of GR, thereby effectively doubling the size of the binding pocket. 132 
PPARγ
A NR that is well-known for having one of the largest orthosteric binding-pockets is PPARγ. The PPARγ pocket is composed of three sub-pockets which have a combined volume of >1200 Å 3 . 133 PPARγ plays an important role in energy homeostasis and inflammation and therefore modulating its activity can be beneficial in e.g. obesity and diabetes. 134 Hughes et al. discovered that at high concentrations the agonist MRL-20 still increased the interaction between PPARγ and coactivator when the orthosteric site was blocked using a small covalent modifier. 135 Using NMR and TR-FRET they confirmed that MRL-20 binds with high affinity to the orthosteric site and with lower affinity in an adjacent pocket, in both cases causing agonistic behavior. 135 The agonistic behavior of the first binding site is caused by direct stabilization of H12 and the AF-2 surface, whereas the second binding site likely stabilizes H3 which facilitates interactions with the loop between H11 and H12 and with that causes stabilization of the coactivator binding region. 135 Covalent modifiers with different sizes and chemical properties were used to define the binding site of MRL-20 more precisely ( Figure 6D ). 133 Another example where one compound is able to bind two connected sites at the same time in the PPARγ LBD is the flexible ligand T2384. 136 In the crystal structure, T2384 is both observed in a U-shape in the canonical LBP and in a S-shape in the canonical LBP in combination with an extra molecule in the alternate site ( Figure 6E ). 136 By making mutant proteins that lack one of the two binding sites, it was elucidated that the combined antagonist/agonist behavior that is observed for this compound in the native protein is caused by an agonistic effect of binding in the orthosteric pocket and an antagonistic effect of binding in the connected allosteric pocket. 136 These binding-modes were confirmed with NMR where it was concluded that both the U and S compound-conformation in the orthosteric pocket exist when adding one equivalent of the compound and the alternate binding site gets populated when adding more than one equivalent. 137 In addition to the instances where one compound binds to both the orthosteric and a connected alternate site, there are also a couple of examples where a synthetic ligand and a naturally occurring lipid together occupy the two pockets of PPARγ. 138, 139 
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PXR
Finally, the pregnane X receptor (PXR) also has a unique way in which its orthosteric binding pocket can be expanded. 140 PXR is known for binding structurally diverse ligands and with that serving as a hydrophobic toxin sensor. 141 Both 17α-ethinylestradiol (EE2), which is used as the active component in contraceptive pills, and trans-nonachlor (TNC), a pesticide, are poor agonists for PXR. However, when these compounds are combined they trigger PXR activation almost as efficient as SR12813 which is a well-characterized PXR full agonist ( Figure 6F ). 140, 142 This cooperative effect has been studied both by functional assays in cells and by biochemical assays that focus on compound binding, isothermal titration calorimetry, and coactivator recruitment, fluorescence anisotropy. 140 In the crystal structures of PXR with EE2 with and without TNC, it can be appreciated that TNC occupies a portion of the LBP that is only accessible when EE2 is bound. 140 This observation is in agreement with other findings in which LBPs can adjust their size to adopt different-sized compounds (i.e. 143 ), but it is the first time that such an effect occurs for cooperative binding of supramolecular interacting compounds. 140 
Dual site binding
In addition to the canonical LBP, ligands were also found that can bind both to the orthosteric site and to another, surface exposed, site on the LBD (Figure 7) . Although the function of the binding to these secondary binding sites is frequently not fully understood yet, some of these ligands were shown to have the capacity to modulate the NRs in a non-traditional way. A number of crystal structures of NRs have been reported with an additional ligand present in the hydrophobic groove of the coactivator binding site e.g. hydroxytamoxifen in complex with ERβ. 99 Generally, this ligand binding to the AF-2 site directly prevents coactivators from binding. For the scope of this review, these examples were not included here and we will primarily focus on the other secondary sites which modulate the receptor via allosteric mechanisms.
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Figure 7. Overview of small molecule ligands binding both to the orthosteric site of NRs and to an allosteric site, located at another structural element of the LBD of the NR. The protein structure of VDR bound to lithocholic acid (LCA) was used as a reference structure, showing the orthosteric ligand in red (PDB: 4Q0A). The structures of PPARα bound to WY-14643 (PDB: 4BCR) and TRα bound to T3 (PDB:
4LNW) were superimposed on this structure to visualize the relative positions of the allosteric ligands.
VDR
The vitamin D receptor (VDR), in addition to its binding to the endogenous ligand vitamin D, also acts as a sensor for the toxic secondary bile acid lithocholic acid (LCA). 144 LCA acts as an agonist for VDR which, in turn, facilitates the clearance of LCA metabolites. A recent crystal structure of zebrafish VDR LBD cocrystallized with LCA showed LCA to bind both in the orthosteric pocket as well as to a surface exposed site near the cofactor binding site (between L1-3, H2' and H3) ( Figure 7) . A combination of biological, computational and structural analysis showed that both sites have to be occupied by LCA for it to act as a VDR agonist. The LCA molecule at the secondary site does not interact with H12 directly but is in close proximity of the coactivator. Comparison of the B-factors of the crystal structures of VDR bound to either one or two LCA molecules showed that the presence of both LCA molecules leads to a stabilization of H12, the loop between H11 and H12 and the cofactor. Therefore, binding of a ligand to this site might reveal a mechanism of ligands to induce coactivator selectivity. 145
PPARα
The potent and PPARα-selective agonist WY-14643 (also known as pirinixic acid) was shown to inhibit NF-κB activity and decrease anti-inflammatory responses. In addition to binding to the orthosteric M A N U S C R I P T
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pocket, WY-14643 binds to an additional binding site in a pocket between H2', H3 and the loop between H11-H12 ( Figure 7) . Using mutational studies, it was shown that binding of the second ligand significantly enhances the activation of PPARα. Because the second ligand is not in contact with H12 directly, the increased activation was further investigated using MD. In this simulation, WY-14643 stabilized the otherwise flexible Ω-loop (between H2 and H3) which, in turn, indirectly stabilized H12. 146 This indirect modulation of H12 via another part of the protein has already been reported earlier in literature for this receptor class. Orthosteric ligands of PPARγ have been shown to stabilize the Ω-loop and β-sheet region in PPARγ, both leading to the stabilization of H12. [147] [148] [149] [150] 
TRα
In 2011, HDX studies were used to show that the natural ligand of the thyroid receptor (TR), triiodothyronine (T 3 ), was likely to also bind in a region of the protein between H9, H10 and H11, located at the opposite site of the AF-2. 151 Three years later, the crystal structure was solved of TRα with T 3 bound to the orthosteric pocket and either T 3 or T 4 located at the earlier predicted position (Figure 7 ). 152 The same group also showed that in an earlier solved crystal structure of the TRβ-selective ligand GC-24 in complex with human TRβ, an additional GC-24 molecule was similarly present in this region. The undefined electron density was initially presumed to be an artifact. 152, 153 Interestingly, the position of this binding site is the same as the predicted binding site of the F-domain of TRα. It is, therefore, hypothesized that the secondary binding site suppresses the activation of TRα when there is a high concentration of ligand present by preventing recruitment of certain cofactors. 152 In addition, T 3 also binds to other NRs such as the androgen receptor (AR) and ER 154 . Interestingly, when AR was cocrystallized with both 5-alpha-dihydrotestosterone and T 3 , another allosteric pocket was found for T 3 at the other side of H9 compared to the TRα structure. 155 
Alternative pockets in the LBD
The two previously mentioned classes of LBD allosteric sites are either an expansion of the orthosteric site or a secondary binding site for an orthosteric ligand (dual site binding). The third class, discussed below, deals with allosteric pockets on the LBD fully independent from the orthosteric pocket in terms of the type of ligand or spatial overlap. Such allosteric sites are known and structurally described for RORγt, RXR, and AR (Figure 8) . Of course, it should be noted that nevertheless, the actual ligand binding to the orthosteric and allosteric pockets could potentially still influence another, because of allosteric effects.
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Figure 8. Overview of NRs targeted via alternative allosteric pockets. A) RORγt with MRL-871 (overlay with the protein with T0901317 (PDB: 4YPQ & 4NB6)). B) RXRα with K-8008 (overlay with the protein with 9-cis retinoic acid (PDB: 4N8R & 1FBY)). C) AR with T3 and DHT (PDB: 2PIT). The orthosteric ligands were shown in red (the licorice representation was used if the ligand was used as a reference compound in the orthosteric site, a spherical representation is used if the ligand is actually present in the crystal structure) and the allosteric ligands in blue. Also, a selection of reported RORγt, RXRα, and M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
RORγt
Retinoic acid related orphan receptor γ t (RORγt) is a key regulator protein for the development of T cells into Th17 cells, which results in tissue inflammation by the excretion of pro-inflammatory cytokines such as IL-17a. [156] [157] [158] Inhibition of RORγt has, therefore, been found to be a promising strategy in the treatment of autoimmune diseases by diminishing the inflammatory response. 159 Many synthetic small molecule inverse agonists for RORγt have been identified in literature, most of them targeting the orthosteric LBP. 160, 161 However, a few years ago a novel acyl-indazole series of RORγt modulators was disclosed by the company Merck/MSD containing a different chemotype in comparison with the already known modulators. 162 Scheepstra et al. identified that these ligands were binding at an alternative binding pocket in the LBD of RORγt. 163 For four of these acyl-indazole ligands (MRL-871, MRL-299, MRL-367, MRL-673), a high resolution crystal structure has been elucidated, in which it can be clearly observed that these modulators bind in an allosteric binding site, distal to the orthosteric binding pocket, at the position where H12 is normally located in its agonistic conformation. This allosteric binding site is shown illustratively for MRL-871 in Figure 8A . The allosteric pocket is formed by H4, H5, H11 and the repositioned H12, which has a unique conformation by folding back over the ligand. In this conformation, the recruitment of coactivators to the AF-2 is prevented. Via this binding mode, the allosteric ligands are functionally acting as inverse agonists with a similar effect as regular orthosteric inhibitors, but in contrast, not in competition with the orthosteric ligands. The acyl-indazole ligands interact with the allosteric pocket mainly via hydrophobic interactions and additionally via H-bonding between the carboxylic acid moiety of the ligand and the Q329 side chain (H3) as well as the main chain amide of A497 and F498 (H12) of the protein. In addition to structural studies, the allosteric modulators were also tested in time-resolved fluorescence coactivator recruitment (TR-FRET) assays and cellular assays, which showed IC 50 values in the nanomolar range. This means that these compounds can be considered as NR allosteric compounds with a potency that reaches clinical demands.
With the discovery of these RORγt allosteric ligands, follow-up research on these compounds has been performed by many companies and research groups, most extensively by Genentech, Glenmark Pharmaceuticals and Ouvry et al. Genentech performed an extensive SAR study around the MRL series of compounds, varying the indazole core and also making changes to the carboxylic acid and 3-acylarene moiety. 164 They specifically attempted to improve the selectivity for RORγt over other NRs, since a remarkable cross-reactivity with PPARγ was observed for the MRL derivatives. 163 From this study, GNE-0946 and GNE-6468 ( Figure 8 (Figure 8 ) as one of the best hits. 165, 166 The compounds were tested in biochemical TR-FRET assays, where one of the compounds showed an IC 50 value of less than 50 nM.
Finally, Ouvry et al mainly focused on improving the metabolic stability of MRL by replacing the heterocyclic amide linkage, since related compounds have shown in vivo instability due to hydrolytic cleavage. 167 For this purpose, different linkers were incorporated on a reverse indazole scaffold, which was derived from one of the MRL analogs, and the library was screened in a RORγt/Gal4 cell-based assay. Incorporation of an ether linker, compound 27 (Figure 8) , resulted in the most potent ligand. Furthermore, the ligand was also tested in phototoxicity assays where it turned out to have a phototoxic irritancy factor above the toxic level, which could not be improved by some further structural changes.
Interestingly, the crystal structure of RORγt with phenoxyindazole 27 was elucidated which revealed binding to the same allosteric pocket as MRL-871 in a similar orientation. 167
Nur
Nurr1 and Nur77, two closely related orphan NRs belonging to the NR4A family, are transcription factors that are involved in many physiological functions, including innate immune cell differentiation, brain functions and metabolism. 168 In contrast to most other NRs, Nurr1 and Nur77 have long been considered to lack a canonical LBP, since the X-ray crystal structures of the LBD show no physical space in the region where other NRs typically bind their ligands. [169] [170] [171] However, recently de Vera et al. and Windshugel showed, using comprehensive NMR spectroscopy, HDX-MS studies and MD simulations, that the LBP of Nurr1 is dynamic and that the pocket allows binding of unsaturated fatty acids by expanding from the collapsed conformation. [169] [170] [171] A recent study indicates that Nurr1 can also be allosterically modulated via an alternative binding pocket, at a similar position on the LBD as discovered for RORγt. Two crystal structures were solved showing two different cyclopentenone prostaglandins (cyPGs) covalently bound to C566 of Nurr1. Binding of the molecule resulted in a significant shift of H12 compared to the apo structure. In an in vitro luciferase reporter assay, cyPGs enhanced the transcriptional activity of Nurr1 in HEK293T cells. 172 
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relevant strategy for the treatment of this type of cancer. Currently, most AR antagonists act by binding to the canonical LBP, but often resistance to these antiandrogen drugs is developed over time in cancer patients. 179 Therefore, there is a high demand for alternative strategies to target AR.
Around a decade ago, an allosteric binding site in the AR was discovered, termed binding function-3 (BF-3). This hydrophobic binding site has a size that is comparable to the AF-2 site and is located at the junction of H1, the loop of H3-5 and H9, adjacent to AF-2 ( Figure 8C ). 179 Estebanez-Perpina et al. used a fluorescence polarization-based assay in combination with a crystallographic screening approach, in which a large library screening was performed and three inhibitors were identified; flufenamic acid (FLUF), triiodothyronine (T3), which was already discussed as a TRα dual site binder, and triiodothyroacetic acid (TRIAC) (Figure 8 ). 179, 180 These compounds were shown to preferentially interact with the BF-3 site (IC 50 values ~50 μM in FP assays) and to have some minor cross-talk to the AF-2 site. A number of follow-up studies were performed by Cherkasov et al 179, [181] [182] [183] [184] , specifically focused on improving the affinity and selectivity for the BF-3 site, while also inhibiting prostate cancer cell growth.
Recently, VPC-13566 ( Figure 8 ) was found as a highly potent (IC 50 = 50 nM) and selective compound, also inducing a significant inhibition of cancer cell growth. 185 Although the BF-3 site is an allosteric one, the conformational change induced in the AR protein appears to be limited. Recently it was found that the way in which the BF-3 site targeted compounds regulate AR activity is via the inhibition of the binding of co-chaperones (Bag-1L 186 , FKBP52 187 and SGTA 185 ), which normally interact with the AR LBD via the BF- The LBD is presently the most promising NR domain for allosteric targeting due to the high affinities and the functional effects of the allosteric compounds that have been found. In addition, there is considerable structural information available for this domain, making de novo drug synthesis, computational guided studies, and medicinal chemistry more straightforward. Nevertheless, the scarcity of full-length structures and the absence thereof in the presence of allosteric ligands, still limits a concise delineation of the allosteric effects on the multi-domain protein level for these new kind of compounds.
Allosteric modulation via nuclear receptor dimerization, mainly via the LBD, has delivered interesting entries for drug development that could be further investigated. To date, the mechanism by which the activation of specific dimers is controlled is still rather poorly understood. The structural diversity of the amino acid residues present at the dimerization interface between NRs is significant. Therefore, the possibility arises to generate synthetic ligands that can selectively bind to the dimerization interface to either stabilize or inhibit specific homo-and heterodimer formation. These synthetic ligands can serve as interesting approaches to target specific pathways, but also to fundamentally understand the importance of the protein dimers.
Although most success in NR allosteric targeting has been on the LBD, other strategies such as allosteric Reflecting on the allosteric mechanisms found for other receptor classes, it becomes clear that NRs possibly also harbor analogous sites with the potential to be similarly allosterically modulated. To date, the vast majority of these approaches, such as bitopic ligands and covalent attaching, have remained unexplored for NRs while the potential for drug discovery can be substantial. Allosteric sites that are in close proximity of the canonical LBP can be targeted by bitopic ligands to more accurately force a desired biological response. Additionally, for NRs with an expanded orthosteric site, the orthosteric ligand can be combined with pharmacophores that occupy directly neighboring pockets. This will ultimately potentially result in a modulation of efficacy, enhanced affinity, and selectivity of the ligand for the specific NR. These type of ligands can, therefore, reduce the cross-reactivity of ligands to other NRs, which remains a serious problem in NR research. 190 Also covalently attachment of molecules is an interesting approach to target NRs. Covalent modulators have the potential to more selectively target NRs using a lower dose, and perhaps also specifically target NR mutants.
A major challenge for the field is the actual discovery of such allosteric ligands, which is in part due to the high potency of orthosteric ligands, biasing screening campaigns. Several entries could be explored in order to identify allosteric modulators more easily. (1) By blocking the orthosteric site with a transcriptionally active or silent covalent modulator, NRs can subsequently only be modulated using an allosteric ligand, which can then be detected by conventional screening assays. (2) By (temporary) covalent tethering of compounds at a specific, allosteric site of the protein.
(3) By exploiting the orthosteric ligand as entry for generation of bitopic ligands for both expanded LBPs and pockets that are in close proximity. (4) Besides the above mentioned specific techniques and targets, also more diverse and directed screening methods, such as those based on computational approaches, fragment-based screening, and phage display could be further optimized or developed towards allosteric site targeting.
NRs have been shown to harbor multiple allosteric sites that can potentially be used for drug discovery. 
